 The study evaluated the effectiveness and side effects of Rituximab intravenous immunoglobulin, IVIG, combination treatment in five patients with epidermolysis prolosa-requisita, EBA, resistant to conventional treatment. The results showed that mean skin involvement, mucosal involvement, and disease severity scores decreased after a mean follow-up of 22.6 months range, 10 to 28 months. In an analysis performed during months 24 to 28, the number of CD-19 positive B cells was found to be below the normal reference range in four patients. The study suggests that Rituximab IVIG combination treatment is effective and safe for treating patients with EBA resistant to conventional treatments. This article was authored by Isoptim, Bengunisa Aki, Isboivad, and others.